QX1206 for Type 2 Diabetes and Fatty Liver Disease
Trial Summary
What is the purpose of this trial?
This is an open label phase 1b trial of QX1206 in patients with T2DM and with NAFLD. Laboratory tests and other measurements will be assessed prior to the first dose of study treatment and throughout the study to determine the recommended phase 2 dose. In addition, the preliminary effects of QX1206 on antidiabetic activity and other metabolic parameters will also be evaluated.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you cannot participate if you take drugs associated with fatty liver disease or certain supplements with potential anti-fatty liver effects.
What data supports the effectiveness of the drug QX1206 for Type 2 Diabetes and Fatty Liver Disease?
Eligibility Criteria
This trial is for adults aged 18-65 with Type 2 Diabetes Mellitus (T2DM) and Non-alcoholic Fatty Liver Disease (NAFLD). Participants must meet specific diabetes criteria, have a Body Mass Index (BMI) between 18 and 45, and functionally healthy kidneys. Women who can bear children need a negative pregnancy test and agree to use contraception.Inclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive QX1206 to evaluate its effects on antidiabetic activity and metabolic parameters
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- QX1206 (Other)